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Abstract
Background: Glycogen Synthase Kinase-3 (GSK-3) a and b are two serine-threonine kinases controlling insulin,
Wnt/b-catenin, NF-B signaling and other cancer-associated transduction pathways. Recent evidence suggests that
GSK-3 could function as growth-promoting kinases, especially in malignant cells. In this study, we have investigated
GSK-3a and GSK-3b function in multiple myeloma (MM).
Methods: GSK-3 a and b expression and cellular localization were investigated by Western blot (WB) and
immunofluorescence analysis in a panel of MM cell lines and in freshly isolated plasma cells from patients. MM cell
growth, viability and sensitivity to bortezomib was assessed upon treatment with GSK-3 specific inhibitors or
transfection with siRNAs against GSK-3 a and b isoforms. Survival signaling pathways were studied with WB
analysis.
Results: GSK-3a and GSK-3b were differently expressed and phosphorylated in MM cells. Inhibition of GSK-3 with
the ATP-competitive, small chemical compounds SB216763 and SB415286 caused MM cell growth arrest and
apoptosis through the activation of the intrinsic pathway. Importantly, the two inhibitors augmented the
bortezomib-induced MM cell cytotoxicity. RNA interference experiments showed that the two GSK-3 isoforms have
distinct roles: GSK-3b knock down decreased MM cell viability, while GSK-3a knock down was associated with a
higher rate of bortezomib-induced cytotoxicity. GSK-3 inhibition caused accumulation of b-catenin and nuclear
phospho-ERK1, 2. Moreover, GSK-3 inhibition and GSK-3a knockdown enhanced bortezomib-induced AKT and
MCL-1 protein degradation. Interestingly, bortezomib caused a reduction of GSK-3 serine phosphorylation and its
nuclear accumulation with a mechanism that resulted partly dependent on GSK-3 itself.
Conclusions: These data suggest that in MM cells GSK-3a and b i) play distinct roles in cell survival and ii)
modulate the sensitivity to proteasome inhibitors.
Background
GSK-3 is a pleiotropic serine-threonine kinase discovered
for its involvement in insulin signaling. Two major iso-
zymes (GSK-3a and GSK-3b) are known and conserved
throughout the species [1]. This kinase is involved in cell
proliferation and survival by controlling the Wnt/b-cate-
nin and growth factors (GFs)-dependent pathways [2].
Constitutive GSK-3-mediated phosphorylation directs
b-catenin to proteasome-mediated degradation [3]. Upon
activation of Wnt signalling, GSK-3 activity is hampered
and unphosphorylated b-catenin accumulates in the cyto-
sol, translocates to the nucleus and promotes gene tran-
scription and cell growth by acting as a co-activator of the
transcription factors TCF/LEF [3,4]. GSK-3 is also inhib-
ited by the action of the Phosphatidylinositol 3-OH kinase
(PI3K)/AKT cell-survival pathway through phosphoryla-
tion on serine 21 (GSK-3a)a n ds e r i n e9( G S K - 3 b)[ 2 ] .
Since Wnt/b-catenin and PI3K/AKT-dependent signaling
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ered a growth-suppressor. By contrast, GSK-3b has been
found essential for cell survival by critically regulating NF-
B transcription factor activity and by protecting cells
from TNFa [5] and TRAIL-induced apoptosis [6-9].
Moreover, while a number of studies demonstrated that
GSK-3 may favor intrinsic apoptosis [10-12], other work
showed that its inhibition could result in cancer cell apop-
tosis and growth arrest, in some cases due to an impaired
NF-B activity [8,13-15]. Taken together, several lines of
evidence indicate that GSK-3 could play a twofold role in
cell survival, depending on the different contexts (for
instance, malignant versus non-malignant cells) or on
whether apoptosis is started by intrinsic or extrinsic
mechanisms [16]. However, a caveat for many of these
studies is that GSK-3a and b isoforms were not evaluated
separately.
Multiple myeloma (MM) is an incurable malignancy of
plasma cells (PC) that clonally expand in the bone mar-
row (BM) [17]. Signaling pathways that might lead to
GSK-3 inactivation and to NF-B activation have been
implicated in MM pathogenesis [18,19]. For instance,
interleukin-6 (IL-6) production by BM stromal cells
(BMSC), which stimulates malignant PC growth and
expression of adhesion molecules, is NF-B-dependent
[20]. Insulin-like Growth Factor-I (IGF-I), an important
growth and chemotactic factor for MM cells [21,22], can
activate both PI3K/AKT and NF-B. Also, Tumor Necro-
sis Factor-a (TNFa) produced in the tumor microenvir-
onment can lend MM cells the ability to escape apoptosis
by up regulating NF-B dependent anti-apoptotic mole-
c u l e s[ 2 3 ] .W h e t h e rG S K - 3p l a y sar o l ei nN F - Ba c t i v a -
tion in MM and other blood tumors upon these and
other stimuli is largely unknown. Moreover, the Wnt/b-
catenin pathway causes MM cells proliferation [24],
suggesting that secreted Wnt proteins in the BM micro-
environment may act as GFs for malignant plasma cells.
Furthermore, active Wnt signaling is also crucially
involved in osteoblast differentiation [25,26]. Interest-
ingly, the Wnt antagonist DKK1 is over expressed in MM
patients displaying impaired bone formation and bone
lytic lesions [27]. In this scenario, GSK-3, by inhibiting
Wnt signaling, should be a growth brake for MM cells
but also a negative regulator of osteoblastogenesis. Thus,
the use of GSK-3 inhibitors to by-pass the DKK1-
mediated Wnt signaling block on osteoblast precursors -
that has been proposed with the aim to slow down the
progression of myeloma bone disease [28,29] - could be
hazardous. It is hence important to study both the role of
GSK-3 in MM cell growth as well as the effects of its
inhibition on the MM cell-tumor microenvironment
interactions. Likewise, the investigation of the potential
regulation of drug-induced cytotoxicity by GSK-3 -
expected to occur in light of its role in the NF-B
signaling - would provide hints to determine the feasibil-
ity of this potentially useful therapeutic approach in MM
therapy.
With this as a background, the aim of our study was
to analyze GSK-3 role in MM cell growth and survival.
By using selective ATP-competitive small chemical
GSK-3 inhibitors as well as gene knock down by RNA
interference, we investigated the consequences of GSK-3
(a and b) down regulation in MM cells. We found that
treatment of MM cells with GSK-3 inhibitors and GSK-
3b knock down caused growth arrest and apoptosis by
perturbing pivotal signaling pathways. We also found
that the GSK-3 inhibitors and GSK-3a knock down
enhanced the anti-MM cytotoxic effect of bortezomib, a
clinically used proteasome inhibitor.
Results
GSK-3 expression in MM cells
GSK-3a/b (hereafter referred as GSK-3) activity is
mainly inhibited through AKT [30] or S6K1 kinase-
dependent [31] phosphorylation on Ser 9 (GSK-3b)a n d
21 (GSK-3a). Since MM cells receive signals that acti-
vate these two kinases, we investigated the expression of
total and serine-phosphorylated (inactive) GSK-3 in
these cells. Protein lysates were obtained from PBMC of
4 healthy subjects, normal in vitro generated PC (nPC),
9 primary MM samples (CD138
+ malignant PC), 4 MM
cell lines (MMCLs); immunoblot analysis of total and
serine-phosphorylated GSK-3 was then performed. As
shown in Fig. 1A, we noticed an abundant expression of
total GSK-3 in PBMC and nPC, both of the a and of
the b isoform. In some MM cells from patients (namely
cases 1, 2, 7 and 9) the GSK-3b isoform was moderately
less expressed. This difference was seemingly more
evident in the U-266, RPMI- 8226 and INA-6 cell lines.
GSK-3 phosphorylation in MM cells
We observed that the GSK-3b isoform resulted to be
more phosphorylated on Ser 9 than GSK-3a on Ser 21,
both in normal and in malignant cells, suggesting that
its catalytic activity is buffered down. Since GSK-3 tyro-
sine phosphorylation indicates its activation, to further
confirm these results, we performed WB analysis of the
levels of phopsho-Tyr 279 GSK-3a and phospho-Tyr
216 GSK-3b on protein lysates of patients 7, 3 and 1. As
shown in Fig. 1B, primary MM cells from three patients
displayed a prevailing tyrosine phosphrylation of GSK-
3a, whereas the levels of phospho-Tyr GSK-3b were
barely detectable.
GSK-3 subcellular localization in MM cells
We next analyzed the intracellular localization of GSK-3
in malignant PC by confocal immunofluorescence (IF).
In resting non-malignant cells GSK-3 localizes mostly in
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sent in the nucleus and other organelles where they
exert specialized functions [32,33]. However, in some
tumors, GSK-3b was found localized mostly in the
nuclear compartment [14,34]. In MMCLs (OPM-2,
INA-6, U-266 and RPMI-8226) GSK-3 was present in
the cytosol (more in OPM-2 and U-266) and in the
nucleus (more in INA-6 and RPMI-8226 cells); in pri-
mary malignant PC from 3 patients (indicated as MM1,
MM9 and MM10) GSK-3 was found to be scarcely
localized in the nucleus, much more in the cytosol and
also close to the cell membrane (Fig. 1C and 1D); in
control BMMC the intracellular distribution of GSK-3
was mostly cytosolic and/or with a speckled-like nuclear
pattern and with very little presence at the plasma
membrane edge (Fig. 1E).
Effects of GSK-3 inhibitors on GSK-3 activity in MM cells
To investigate GSK-3 function in MM cells we used the
well characterized in vitro and in vivo, ATP-competitive,
Figure 1 GSK-3 expression, phosphorylation and localization in MM cells. (A) WB for total GSK-3a and b (top panels), phosphorylated GSK-3a
(on Ser 21) and GSK-3b (on Ser 9) (middle panels), and b-actin as loading control (bottom panels) in (from left to right): 4 PBMC samples of healthy
subjects, non-malignant in vitro-generated PC (nPC), CD138
+ purified PC from 9 MM patients, 4 MMCLs; (B) WB for total GSK-3a and b (top panels),
phosphorylated GSK-3a (on Tyr 279) and GSK-3b (on Tyr 216) (middle panels) and b-actin as loading control (bottom panels), in three primary MM
plasma cell samples (MM 7, 3, 1). (C-E): GSK-3 immunostaining and confocal microscopy analysis in MMCLs OPM-2, INA-6, U-266 and RPMI-8226 (C),
three CD138+ primary malignant PC from patients (MM1, MM9, MM10) (D) and BMMC (E). In the merged images GSK-3 is detected by green
fluorescence and nuclei are in blue. Scale bars = 10 μm. For all the images: 600× magnification, oil objective.
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Page 3 of 14GSK-3 chemical inhibitors SB216763 and SB415286.
These compounds were tested in previous studies for
their activity against a panel of several different kinases
(>20), displaying a fairly high specificity for GSK-3a and
GSK-3b [35,36]. First, we tested the efficacy to inhibit
G S K - 3b yc u l t u r i n gM Mc e l l sO P M - 2a n dR P M I - 8 2 2 6
in the presence of the two compounds. These two cell
lines were chosen since they displayed lower phospho-
serine GSK-3a/b levels (and thus higher activity) than
the others. Total GSK-3 activity (a plus b isozymes) was
then determined on cellular protein lysates after 24
hours using a radioactive kinase assay. The inhibitory
activity of SB216763 and SB415286 was assayed against
human recombinant GSK-3b (hrGSK-3b)p r o t e i n ,a sa
control. As shown in Fig. 2A (OPM-2 cell line) and Fig.
2B (RPMI-8226 cell line), both the inhibitors hampered
hrGSK-3b (leftmost graph) and endogenous (rightmost
graph) GSK-3 activity (p < 0.05, n = 3). Similar results
were obtained using U-266 and INA-6 cells (not
shown), demonstrating that these compounds can effi-
ciently inhibit the active pool of GSK-3 in MM cells.
GSK-3 down regulation decreases MM cell growth and
survival
We next checked the effects of the GSK-3 inhibitors on
malignant PC growth by treating MM cells with increas-
ing concentrations of SB415286 or SB216763. In these
conditions, all the MMCLs tested displayed a dose-
dependent decrease of their growth as determined by
reduced thymidine incorporation (U-266, INA-6) (p <
0.05, n = 4) (Fig. 2C) and BrdU staining (RPMI-8226,
U-266, INA-6) (p < 0.05, n = 5)(data not shown), indi-
cating that GSK-3 may function as a growth-promoter
in these cell lines. Data were represented as percent of
untreated cells (made equal to 100% of incorporation of
3H-thymidine evaluated as counts per minutes or 100%
of BrdU fluorescence staining evaluated by FACS analy-
sis, as specified in Methods).
Then, we investigated whether apoptosis could be one
mechanism of growth inhibition in GSK-3 inhibitor-
treated MM cells. Annexin V staining and FACS analy-
sis experiments using U-266, RPMI-8226 and INA-6
cells showed that treatment with SB415286 resulted in a
moderate though significant reduction of cell viability
(p < 0.05, n = 5) (Fig. 3A, graph on the left). Impor-
tantly, at this concentration of SB415286 normal
PBMCs did not display apoptosis as compared to
untreated samples (Fig. 3A, graph on the right). To
further validate the above results, we measured the elec-
trochemical gradient across the mitochondrial mem-
brane in the absence or presence of GSK-3 inhibition (4
or 8 μM SB415286). Experiments carried out with the
JC-1 dye [37] showed that GSK-3 inhibition in INA-6
and U-266 cells caused the disruption of the
mitochondrial membrane potential (increase of the
number of cells stained with JC-1 green-fluorescent
monomers, p < 0.01, n = 5) (Fig. 3B). Furthermore, WB
analysis of protein lysates obtained from SB216763-trea-
ted RPMI-8226 cells revealed that GSK-3 inhibition was
associated with a significant reduction of the amount of
phospho-Tyr 279 GSK-3a and phospho-Tyr 216 GSK-
3b, indicating that the compound efficiently inhibited
the autocatalytic activity of GSK-3, in agreement with
previous studies [38,39] and with our above described in
vitro kinase assays. To note, SB216763 caused activation
of the intrinsic mitochondria-dependent apoptosis evi-
denced by Poly (ADP ribose) polymerase (PARP) clea-
vage and a significant increase of Smac/DIABLO
cytoplasmic protein levels (Fig. 3C, top panels). Also
SB415286-treatment of INA-6 cells caused apoptosis
and PARP cleavage, time-dependently (Fig. 3C, bottom
panels).
Inhibition of GSK-3 increases b-catenin and phospho-
ERK1, 2 levels in MM cells
Next, we investigated the effects of SB216763 and
SB415286 (not shown) treatment of U-266 MM cells on
GSK-3-related signaling pathways by WB experiments
using cytoplasmic and nuclear protein lysates (Fig. 3D).
The GSK-3 inhibitors caused a significant increase of
b-catenin levels, in the cytoplasm and in the nucleus, as
expected - again showing a remarkable inhibition of GSK-
3 Tyr phosphorylation. Interestingly, in the presence of
GSK-3 inhibition an accumulation of GSK-3 in the cytosol
was observed. We also looked at the ERK1/2 pathway, an
important proliferative cascade for MM cells, since GSK-3
was shown to negatively regulate it in the myocardial mus-
cle [40] and in immune cells [41]. Indeed, ERK1/2 phos-
phorylation was also affected by GSK-3 inhibition - even if
in a slighter fashion - with mild increase of the phospho-
Thr202/Tyr204 ERK1, 2 nuclear pool, indicating a role -
likely minor - for GSK-3 in this context (Fig. 3D).
Molecular sequelae and effects of GSK-3 inhibition on
bortezomib-dependent cytotoxicity in MM cells
Since GSK-3 controls MM cell survival, we next checked
whether it could modulate the pro-apoptotic effects of the
proteasome inhibitor bortezomib (BZ), a clinically used
anti-MM agent that down modulates growth-promoting
pathways, triggers mitochondria-dependent apoptosis [42]
and interferes with MM cell-BMSC interactions [43]. To
this aim, MM cells (U-266 and RPMI-8226) were treated
with either 4 μM SB415286, either 5 nM BZ or both and
annexin V staining and FACS analysis were used to quan-
tify apoptosis. As shown in Fig. 4A, the simultaneous
treatment of MM cells (U-266 and RPMI-8226) with the
GSK-3 inhibitor and BZ caused a moderate but significant
increase of apoptosis in both MM cell lines as compared
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< 0.05, n = 3 for both series of experiments). Immunoblot
analysis of survival and BZ-regulated MM molecules con-
firmed that SB415286 caused an enhanced PARP cleavage
in the nucleus compared to untreated samples. BZ expo-
sure of MM cells was accompanied by a more pronounced
PARP cleavage and, interestingly, by an increase of nuclear
phospho-Ser 473 AKT levels, a reduction of total AKT
and of the anti-apoptotic BCL-2 family member MCL-1
protein levels. These effects of BZ were already described
in other studies [44,45], even though in certain cancer cell
types BZ was shown to reduce phospho-Ser 473 AKT
levels [46,47]. Remarkably, the treatment of MM cells with
GSK-3 inhibitors together with BZ resulted in an even
further increase of PARP cleavage and reduction of
phospho-Ser 473 AKT levels, total AKT and MCL-1 pro-
tein levels (Fig. 4B).
GSK-3a and b silencing by RNA interference unveils a
different role for the two isoforms in MM cell survival
To further analyze the role of GSK-3 in MM cell growth
we performed RNA interference experiments to knock
down GSK-3a and GSK-3b protein expression levels in
U-266 cells. As shown in Fig. 5A, we could achieve a sig-
nificant reduction of GSK-3a (left panel) and GSK-3b
(right panel) protein levels, peaking 48 hours and lasting
as long as 72 hours after U-266 MM cells nucleofection
with specific GSK-3a or GSK-3b-directed small interfer-
ing RNA oligos. The efficiency of transfection was high
(transfected cells ranged from 80% to > 90%) in all the
Figure 2 Effects of GSK-3 inhibitors on MM cell proliferation. (A, B) Graphs showing representative in vitro kinase assays performed using human
recombinant GSK-3b (hrGSK-3b) and total protein lysates (+ = 1 μg, ++ = 4 μg) of OPM-2 cells (A) and RPMI-8226 cells (B) that were cultured with the
two specific GSK-3 inhibitors, SB216763 at 10 μM and SB415286 at 4 μM. The graphs show a remarkable inhibition of both hrGSK-3b protein (leftmost
graphs) and endogenous GSK-3 kinase activity (rightmost graphs) (y axis: counts per minute). Data represent mean ± SD, n =3 .*i n d i c a t e sp <0 . 0 5b y
one-way ANOVA test. (C) Dose-response graphs of U-266 (left) and INA-6 cells (right) incubated for 48 hours with increasing concentrations of
SB415286. Cell proliferation was assessed by
3H-thymidine-incorporation assay. Data represent mean ± SD, n =4 ,*i n d i c a t e sp < 0.05 by one-way
ANOVA test.
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ples, either un-transfected or transfected with blank buf-
fer or with scrambled RNA oligonucleotides did not
show significant alterations of the protein kinase levels.
Since as markers of nucleofection efficiency we used
fluorescent RNA oligos that had an emission spectrum
overlapping with those of propidium iodide, annexin V
and JC-1, we used light microscopy as an alternative
mean to analyze cell viability; this assay revealed that
GSK-3b-silenced cells were more irregularly-shaped with
picnotic nuclei as compared to cells transfected with
scrambled or GSK-3a-targeting siRNAs (Fig. 5B, left
panels). Moreover, the quantitative analysis of cellular
morphology and granularity by FACS showed that GSK-
3b-silenced samples displayed approximately a 1.4 fold
increase in the percentage of dying [low forward scatter
(FSC)/high side scatter (SSC)] cells as compared to sam-
ples transfected with scrambled siRNAs (p < 0.05, n = 6).
This effect was not evident when GSK-3a was knocked
down (Fig. 5B, middle panels; in the rightmost graphs
Figure 3 GSK-3 inhibition causes MM cell apoptosis and disruption of the mitochondrial membrane potential. (A) Histograms showing
the percentage of surviving (annexin V negative) U-266, RPMI-8226 and INA-6 cells (left graph) and of normal PBMC control cells (right graph)
after treatment without (black bars) or with (white bars) 4 μM SB415286 for 48 hours. Data represent mean ± SD, n = 5 (cell lines) or 4 (PBMC).
* indicates p < 0.05 by Student’s t-test. (B) Histograms showing FACS analysis of the amount of JC-1 monomer-containing, green fluorescent-
INA-6 cells (left graph) or U-266 cells (right graph), treated with the same conditions as in A. Data are expressed as ratio over untreated cells.
Data represent mean ± SEM, n = 5. * indicates p < 0.01 by Student’s t-test. (C) Representative WB analysis of phospho Tyr 279 GSK-3a and
phospho Tyr 216 GSK-3b, total GSK-3, PARP cleavage and Smac/DIABLO protein expression on cell lysates of RPMI-8226 cells grown with 5 μM
or 10 μM SB216763 for 24 hours (top panels) and WB analysis of PARP protein in INA-6 cells grown with 4 μM SB415286 for 8 and 24 hours
(bottom). b-Actin is used to check protein loading. (D) Representative WB analysis of nuclear (n) and cytosolic (c) proteins from U-266 cells
untreated or treated with 5 μM SB216763, showing the levels of total GSK-3, Tyr phosphorylated GSK-3, b-catenin, total ERK 1/2, Thr/Tyr
phosphorylated ERK 1/2, PARP and nucleophosmin and GAPDH as loading controls.
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silencing of GSK3a did not cause a substantial reduction
of the unprocessed PARP protein as opposed to silencing
of GSK-3b, suggesting that, at basal growing conditions,
only GSK-3b may partially sustain MM cell survival
(Fig. 5C).
GSK-3a knock down empowers bortezomib-induced cell
death
To confirm the results obtained with BZ and GSK-3
inhibitors, we carried out RNA interference experiments
of GSK-3a and GSK-3b subunits in U-266 MM cells; 48
hours after transfection with the targeting siRNAs, cells
were grown for additional 18 hours with or without BZ.
Cells were then analyzed by light microscopy and FACS
for morphological changes indicative of decreased
viability, as above described. Treatment with BZ 5 nM
caused marked apoptosis. Interestingly, knock down of
GSK-3a,b u tn o to fG S K - 3 b, was associated with an
increase of BZ-induced cell death, as evidenced by more
irregularly-shaped cells with picnotic nuclei by light
microscopy (Fig. 5D, left panels). Moreover, we did not
observe significant changes i nt h ep e r c e n t a g eo fl o w -
FSC/high-SSC cells by FACS analysis of GSK-3b-
silenced and BZ-treated cells (Fig. 5D, right panels,
bottom graph), whereas we could detect a statistically
significant decrease of viability in the GSK-3a-silenced
and BZ-treated samples (p < 0.05, n = 3) as compared
to scrambled oligos-transfected controls (Fig. 5D, right
panels, top graph). We next analyzed U-266 cell viability
upon silencing of both the GSK-3 isoforms and BZ
treatment. As shown in the graph in Fig. 5E, RNA
Figure 4 GSK-3 inhibition increases MM cell sensitivity to bortezomib-induced apoptosis. (A) Histograms summarizing the data on the
percentage of apoptotic MM cells, evaluated by annexin V staining and FACS analysis, left untreated (white bars) treated with the GSK-3
inhibitor SB415286 (4 μM) (black bars), bortezomib (BZ) 5 nM (black and white dashed bars) or both (black, white-dotted bars). Top graphs:
U-266 cells, bottom: RPMI-8226 cells. Data represent mean ± SEM, n = 3. * indicates p < 0.05 by one-way ANOVA test. (B) Representative WB
analysis of nuclear (n) and cytosolic (c) proteins from U-266 cells untreated, treated with 4 μM SB415286, with 5 nM BZ or both, showing the
levels of PARP and cleaved PARP, Ser 473-phosphorylated AKT, AKT and MCL-1. Nucleophosmin and GAPDH were used as nuclear and cytosolic
loading controls, respectively.
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3b expression was associated with decreased MM cell
viability (p < 0.05, n = 3). Remarkably, silencing of GSK-
3a and GSK-3b also augmented the cytotoxic effect of
BZ (p < 0.05, n = 5), confirming the results observed
with the chemical inhibitors.
AKT and MCL-1 are targets of GSK-3 in MM cells
We next checked whether silencing of GSK-3 could lead
to alterations of BZ-controlled pathways, as observed
with the small chemical inhibitors. Immunoblot analysis
showed a substantial reduction of GSK-3b or GSK-3a
isoforms in these experiments (Fig. 5F, lanes 4-6, 8-10).
BZ caused a reduction of AKT and MCL-1 protein
levels (lane 2). Noteworthy, we observed that in both
GSK-3a and GSK-3a/b double-silenced cells, AKT pro-
tein levels were also reduced. As a consequence, silen-
cing of GSK-3a or GSK-3a plus GSK-3b was seemingly
associated with a slight reduction of phospho-Ser 473
AKT (lanes 4 and 5). This effect was not as obvious in
GSK-3b-only silenced cells (lane 6). BZ treatment of
GSK-3a and GSK-3a/b double-silenced cells was asso-
ciated with a marked reduction of AKT protein levels
(lanes 8, 9). BZ also caused an increase of phospho-Ser
Figure 5 Effects of GSK-3a and b knockdown by RNA interference on MM cell survival. (A) WB analysis of the levels of GSK-3a (left panels)
or GSK-3b (right panels) upon nucleofection with: un = untransfected; scr = scrambled siRNAs oligos; GSK-3a or GSK-3b=GSK-3a or GSK-3b-
directed siRNAs oligos. (B, left panels) Light microscopy microphotographs of U-266 cells transfected with scrambled (scr), GSK-3a or GSK-3b-
directed siRNAs oligos. Scale bars = 10 μm. (B, middle plots) Representative dot plot graphs and FACS analysis of U-266 cells transfected with
scrambled (scr), GSK-3a or GSK-3b-directed siRNAs oligos. (B, right panels) Histograms summarizing the results of FACS analysis of U-266 cells
transfected with scrambled (scr) siRNAs oligos, GSK-3a (top) or GSK-3b (bottom)-specific siRNAs oligos,. In y-axis dead cells are cells displaying a
low FSC/high SSC cyto-morphological profile. Data represent mean ± SEM, n = 6. * indicates p < 0.05 (Student’s t test). (C) Representative WB
analysis of the levels of unprocessed PARP after nucleofection of U-266 cells with: scrambled, GSK-3a or GSK-3b siRNAs oligos. (D) Light
microscopy microphotographs and histograms summarizing the results of FACS analysis of U-266 cells transfected with scrambled (scr), GSK-3a
or GSK-3b-directed siRNAs oligos and treated with 5 nM BZ. In y-axis dead cells are cells displaying a low FSC/high SSC cyto-morphological
profile. Data represent mean ± SEM, n = 3. * indicates p < 0.05 (one-way ANOVA test). (E) Histogram plot summarizing the results of the FACS
analysis of U-266 cells transfected with scrambled (scr) or GSK-3a/GSK-3b-directed siRNA oligos and treated with 5 nM BZ. In y-axis dead cells
are cells displaying a low FSC/high SSC cyto-morphological profile. Data represent mean ± SEM, n = 3. * indicates p < 0.05 (one-way ANOVA).
(F) WB analysis of GSK-3a, GSK-3b, AKT, Ser 473-phosphorylated AKT and MCL-1 protein levels in U-266 cells untransfected (lane 1), treated with
5 nM BZ (lane2), transfected with scrambled (scr, lane 3) or GSK-3a/b (lane 4), GSK-3a (lane 5) or GSK-3b (lane 6)-directed siRNAs oligos without
(-, lanes 3-6) or with (+, lanes 7-10) exposure to 5 nM BZ for 18 hours.
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3a isoforms were knocked down, this effect was
decreased (lanes 8, 9). Intriguingly, it appeared that
silencing of GSK-3a somehow favored whereas silencing
of GSK-3b protected against BZ-induced AKT and, even
more, MCL-1 degradation (Fig. 5F, lanes 7-10).
Bortezomib induces GSK-3 activation and nuclear
translocation
Since the above results suggest that GSK-3a can antago-
nize BZ-dependent cell death and as it has been demon-
strated that GSK-3 serine and tyrosine phosphorylation
levels and intracellular localization change upon differ-
ent apoptotic noxae [48], we checked GSK-3 phosphory-
lation and cellular localization in MM cells upon
treatment with BZ. While GSK-3 protein was detectable
mostly in the cytosol of untreated cells, it was visible
both in the nucleus and in the cytoplasm of cells treated
with 5 nM BZ for 18 hours (Fig. 6A, a graph summariz-
ing the scoring results is shown at the bottom; p < 0.05,
n = 3 separate experiments). Most interestingly, WB
experiments demonstrated a marked reduction of Ser
21/9 GSK-3 phosphorylation, both in the cytosol and in
the nucleus, and a slight accumulation of total GSK-3 in
the nuclear compartment, upon BZ treatment (Fig. 6B).
I na l lt h ee x p e r i m e n t s ,B Zw a sa b l et oi n d u c eas i g n i f i -
cant amount of apoptosis, as assessed by WB analysis of
PARP cleavage (Fig. 6B). Since GSK-3 nuclear transloca-
tion has been associated with Tyr phosphorylation,
which in turn depends on GSK-3 activity itself, we next
analyzed by WB the levels of phospho-Tyr GSK-3, total
GSK-3 and nuclear/cytoplasm localization upon treat-
ment with two concentrations (5 μMa n d1 0μM) of
SB216763, 5 nM BZ or both. These experiments (Fig.
6C) revealed that SB216763 efficiently reduced the phos-
pho-Tyr GSK-3 levels in the nucleus and in the cyto-
plasm; BZ caused a shift of phospho-Tyr GSK-3 and
total GSK-3 in the nucleus and, interestingly, treatment
with BZ plus SB216763, while it was still associated with
a reduction of phospho-Tyr GSK-3, prevented the
nuclear shuttling of the kinase.
Discussion
The involvement of GSK-3 in cancer cell biology has
recently been demonstrated. GSK-3 sustains the growth
of malignant blood cells, like chronic lymphocytic leuke-
mia (CLL) [34] and acute myeloid leukemia cells (AML)
[49]. Our data demonstrated that GSK-3 regulates MM
cell growth and survival. Importantly, we also found
that GSK-3 modulates MM cell sensitivity to BZ-
induced apoptosis.
The expression analysis revealed that, in most MM
samples from patients and even more, in all the MMCLs,
GSK-3b protein levels were lower than GSK-3a.T h i s
was not evident in normal controls (PBMC, nPC).
GSK-3b also resulted more phosphorylated in Ser 9 than
GSK-3a in Ser 21 both in normal and malignant samples;
moreover, in the MM samples analyzed for GSK-3 Tyr
phosphorylation, we found that GSK-3b was much less
Tyr phosphorylated than GSK-3a ( F i g .1 A ) .S i n c e
GSK-3b Ser 9-phosphorylation is associated with a
reduction in the enzymatic activity whereas GSK-3b Tyr
216-phosphorylation indicates activation [30], these find-
ings, even if to be validated on a larger number of
primary MM samples, indicate that the GSK-3b isoform
m a yb el e s sa c t i v et h a nG S K - 3 a in normal PBMC and
nPC as well as in MM cells. In these latter cells, however,
we observed also a reduction of GSK-3b expression
that could contribute to a further down-regulation of its
activity. Interestingly, GSK-3a and GSK-3b do not share
the same physiological functions [50]. In particular, GSK-
3a d o e sn o ts u p p l yf o rt h el o s so fG S K - 3 b-dependent
NF-B regulation in GSK-3b knock out cell, whereas it
does in the regulation of the Wnt/b-catenin pathway [5].
Our expression studies also showed that in MM plasma
cells from patients and some MMCLs (OPM-2, INA-6),
GSK-3 was present in the cytosol and partly close to the
cell surface, but rarely in the nucleus (Fig. 1B and 1C).
Although in other types of cancer cells GSK-3 localiza-
tion in the nucleus has been associated to an aggressive
behavior, our data indicate that in MM cells at resting
conditions GSK-3 nuclear functions might not be
selected.
GSK-3 was demonstrated to play an important role in
modulating cell growth in several solid tumors and two
recent studies have shown that B-CLL and Mixed Line-
age Leukemia-associated AML cell survival is greatly
impaired by the inhibition of GSK-3 [34,49]. Our data
indicate that GSK-3 promotes MM cell survival both at
basal and under stressed (proteasome inhibition) grow-
ing conditions (Fig. 2, 3 and 4). Firstly, the results with
the chemical inhibitors SB216763 and SB415286 indicate
that GSK-3 inhibition in MM cells leads to a reduction
of MM cell growth. This effect is achieved despite the
fact that GSK-3 inhibition causes an increase of b-cate-
nin and phospho-ERK levels, which is expected to result
in a growth advantage. Moreover, we have observed that
exposing MM cells to GSK-3 inhibitors could augment
the response to the cytotoxic effects of BZ, a clinically
used chief therapeutic agent in MM therapy. BZ regu-
lates several signaling pathways important for cell survi-
val, among which are the AKT, MCL-1, NF-Ba n dt h e
Wnt/b-catenin-regulated cascades [42]. Our results sug-
gest that GSK-3 might positively regulate the AKT and
MCL-1-dependent survival pathways which are normally
targeted by BZ, since GSK-3 inhibitors cause a reduc-
tion of the BZ-triggered AKT phosphorylation and
MCL-1 degradation. However, even if selective and
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GSK-3a and GSK-3b, rendering difficult to study iso-
form-specific functions; additionally, “off-target” GSK-3-
independent effects could also occur. Nevertheless,
GSK-3a and GSK-3b down modulation by RNA inter-
ference in MM cells substantiated the results found with
the inhibitors. In fact, our data indicated that GSK-3a
and GSK-3b might control MM cell growth, although in
a distinct manner. GSK-3b but not GSK-3a knock
down caused basal MM cell apoptosis whereas GSK-3a
but not GSK-3b knock down was associated with a
trend towards increased BZ-induced apoptosis: this
would suggest unexpected different roles of the two
GSK-3 isoforms in MM cell survival. As mentioned
above, the two GSK-3 isoforms can have overlapping
functions in regulating the Wnt/b-catenin signaling
pathway but not other cascades, such as the NF-Bo n e ,
which is mostly dependent on GSK-3b and is critical for
MM cell survival [5,16]. Even if the analysis of the pre-
transcriptional steps of the NF-B pathway did not
Figure 6 Bortezomib modulates GSK-3 intracellular localization and activation. (A) Immunofluorescence microscopy of INA-6 and U-266
cells untreated or treated with 5 nM BZ for 18 hours and stained for GSK-3 (green fluorescence) and the nuclei (DAPI, blue fluorescence)
showing partial nuclear re-localization of GSK-3 upon BZ treatment. Scale bars = 10 μm. On the bottom, graph showing the percentage of MM
cells scored as having cytosolic only GSK-3 in the untreated (black bars) or 5 nM BZ-treated (white bars) conditions. Data represent mean ± SD,
n = 3. * indicates p < 0.05. (B) Representative WB analysis of phospho Ser 9 GSK-3b/Ser 21 GSK-3a and total GSK-3a/b in nuclear (n) and
cytoplasmic (c) protein fractions from untreated (-) or 5 nM BZ-treated (18 hours) U-266 cells. b-Actin and nuclear PARP are used as markers for
protein loading. (C) Representative WB analysis of phospho Tyr 279 GSK-3a/Tyr 216 GSK-3b and total GSK-3a/b in nuclear (n) and cytoplasmic (c)
protein fractions from untreated (-) or 5 nM BZ-treated (+) (18 hours) U-266 cells, in the presence or absence of 5 μMo r1 0μM SB216763.
GAPDH and nucleophosmin were used as protein loading markers.
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vation (data not shown), it is still possible, as already
reported by other studies [34], that, even in MM cells,
GSK-3b regulates NF-B transcriptional activity directly
on DNA. Moreover, our data suggest that GSK-3a
might control AKT protein turnover, while GSK-3b
could modulate MCL-1 protein stability. Clearly, this
latter effect of GSK-3b - already described in previous
studies [12] - is in contradiction with the evidence that
GSK-3b knock down leads to basal MM cell reduced
viability. Other signaling pathways should therefore be
involved here. In agreement with previous studies, we
have shown that BZ induces a reduction of total AKT
(with the paradoxical effect of increasing its Ser 473
phosphorylation) and MCL-1 protein levels in MM cells.
Interestingly, these BZ-induced biochemical changes
were amplified by the treatment with the GSK-3 inhibi-
tors, which were also able to cause a reduction of AKT
Ser 473 phosphorylation (Fig. 4). Remarkably, we
demonstrated that the siRNA-mediated knock down
of GSK3a and of both the GSK-3 isoforms but not
of GSK-3b alone, was associated with the same changes
of AKT and MCL-1 levels as seen with the inhibitors.
Therefore, our experiments suggest that GSK-3b could
influence MM cell survival through MCL-1 and AKT-
independent mechanisms, while GSK-3a could modu-
late BZ-induced MM cell apoptosis interfering with
pathways controlling AKT and MCL-1 protein levels.
To note, AKT levels have been demonstrated to be con-
trolled by GSK-3 in previous studies [51].
Furthermore, we provided evidence for a functional
link between BZ and GSK-3. Indeed, despite the fact
that BZ induces Ser 473 AKT phosphorylation, it caused
GSK-3 dephosphorylation in Ser 9/21 and its nuclear
migration. However, only a little increase in the GSK-3
Tyr phosphorylation (especially in the nucleus) was
seen. It is possible that the BZ-induced modifications
are not sufficient to trigger a marked Tyr autophosphor-
ylation; alternatively, a full Tyr autophosphorylation
could take place at different time points which were not
explored in the current study. To note, these alterations
of GSK-3 function have also been demonstrated to
occur after cell exposure to other apoptotic noxae and
have been related to the pro-apoptotic effects of this
kinase [48]. Interestingly, BZ-induced GSK-3 nuclear
accumulation seems to depend on GSK-3 activity, since
treatment with SB216763 impaired this intracellular
shift. However, the exact significance of GSK-3 nuclear
migration upon BZ treatment remains to be elucidated.
Since GSK-3 inhibition is accompanied by an increased
sensitivity to BZ-triggered cell death, it is unlikely that
BZ-induced GSK-3 nuclear accumulation triggers a pro-
apoptotic pathway. Oppositely, it is possible that nuclear
GSK-3 antagonizes a BZ-dependent nuclear apoptotic
pathway. Nonetheless, BZ could trigger GSK-3 activa-
tion as a feedback loop to protect MM cells from apop-
tosis. AKT might be Ser 473 phosphorylated through an
unknown, GSK-3-dependent pathway. GSK-3 inhibition
would therefore lead to a reduction of phospho-Ser 473
AKT and increased susceptibility to BZ-induced cell
death. This unexpected scenario would imply that GSK-
3, at basal conditions (to a lesser extent) and in the pre-
sence of BZ (to a larger extent), might positively regu-
late the PI3K/AKT pathway, which in turn is a negative
regulator of GSK-3 - as also suggested by the significant
amount of GSK-3 (especially GSK-3b) Ser-phosphoryla-
tion found in MM cells (Fig. 1A and 6D). In resting
conditions this could represent a regulatory loop
whereby GSK-3 might buffer down its own activity.
However, upon BZ treatment, being Ser 473 AKT phos-
phorylation increased, other PI3K/AKT-independent
mechanism should take place that justify the reduction
of GSK-3 Ser-phosphorylation.
Conclusions
In conclusion, we have herein demonstrated distinct
functions of GSK-3a and GSK-3b in MM cell survival.
We have employed two strategies to inhibit GSK-3a
and b function: the use of selective chemical com-
pounds, which were already extensively characterized, as
well as the more specific RNA interference technology.
We have shown that GSK3a and b might promote MM
cell survival under different conditions and we have
described a link between the action of BZ and GSK-3
providing a mechanistic clue to sustain a viewpoint
whereby this cross-talk may occur. Our data could be
helpful to improve our knowledge of MM pathogenesis
and of the mechanisms of response to novel treatments,
as well as to develop novel anti-MM targeted therapies.
Methods
Patients and cell cultures
Patients were charged to the University of Padova Hospi-
tal. Informed consent was obtained from patients accord-
ing to the declaration of Helsinki and the laboratory
protocol was supervised by the institutional scientific
review board at the Department of Clinical and Experi-
mental Medicine, University of Padova. Malignant
plasma cells were purified using CD138 -coated microbe-
ads (Miltenyi Biotech, Bergish Gladbach, Germany)
according to the manufacturer’s protocols. Peripheral
blood mononuclear cells (PBMC) and bone marrow
(BM) mononuclear cells (BMMC) were obtained from PB
and BM aspirates of healthy donors and processed as
described [52]. Normal plasma cells were generated
in vitro as previously described [52]. MM cell lines OPM-
2 were purchased from the German Collection of Micro-
organisms and Cell Cultures (DSMZ), RPMI-8226 and
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Collection (Rockville, USA); the IL-6-dependent MM cell
line INA-6 was a generous gift of Dr. M. Gramatzki,
Division of Stem Cell Transplantation and Immunother-
apy, University of Kiel, Germany. Cell lines were main-
tained in RPMI 1640 medium supplemented with 10%
fetal bovine serum, L-glutamine, antibiotics (Gibco
Laboratories, Grand Island, NY, USA) under controlled-
atmosphere in incubators at 37°C in the presence of 5%
CO2. Quality controls were made every 8 weeks to check
for Mycoplasma contamination, ploidy, immunopheno-
type and cell morphology.
Chemicals
GSK-3a/b inhibitors SB216763 and SB415286 were pur-
chased from Sigma-Aldrich, Italy. Bortezomib was pur-
chased from LC laboratories, MA, USA.
GSK-3 activity in cell lysates
One-2 μg of whole cell extracts (WCE) were incubated
for 10 min at 30º C with 1 mM GSK-3a/b-specific pep-
tide RRRPASVPPSPSLSRHS(pS)HQRR (Upstate, NY,
USA), in the presence of 50 mM Tris-HCl, pH 7.5, 12
mM MgCl2,1 0μM[ g-
33P]ATP (~3000 cpm/pmol)
(Amersham Biosciences, UK), 0.1 M NaCl, in a total
volume of 20 μl. Samples were spotted onto phospho-
cellulose paper and radioactivity was detected by liquid
scintillation as previously described [52].
mRNA silencing
RNA interference was performed by using small interfer-
ing RNAs purchased from Dharmacon, USA. Briefly,
U-266 cells (2 × 10
6/ml) were nucleofected with the
Amaxa® system according to the manufacturer’s instruc-
tions with siGLO green scrambled siRNAs, on-Target plus
SMART pool oligos against GSK-3a and/or GSK-3b-tar-
geting siRNAs (100 picomoles). (GSK-3a-specific target
sequences: CACAAGCUUUAACUGAGA; GAAGGU-
GACCACAGUCGUA; GAGUUCAAGUUCCCUCAGA;
CUGGACCAACUGCAAUAUUG. GSK-3b-specific target
sequences: GAUCAUUUGGUGUGGUAUA; GCUAGAU-
CACUGUAACAUA; GUUCCGAAGUUUAGCCUAU;
GCACCAGAGUUGAUCUUUG). Cells were immediately
put in pre-warmed RPMI complete medium and left in
culture for different time lapses. Cells were then harvested
and processed to check GSK-3a and b expression by wes-
tern blot (WB) analysis.
Evaluation of growth and apoptosis
In [
3H]thymidine incorporation assay cells were plated
in 96-flat well plates (5 × 10
4/well) with different con-
centrations of GSK-3 inhibitors SB216763 or SB415286.
After 48 or 72 hours [
3H]thymidine was added to the
cultures (10 μCi/well) for the last 12 hours. The [
3H]
thymidine incorporation was evaluated by scintillation
counting by using a top count b-counter (Microbeta
Plus; Wallac). For BrdU staining, 2×10
6 MM cells were
incubated with 10 μM BrdU in PBS for 30 minutes and
afterwards ice-cold PBS was added to stop the incor-
poration. Samples were centrifuged at 409 g for 8 min-
utes at 4°C and pellets were resuspended and fixed in
ethanol 70% in deionized H2O for 12 hours. Samples
were centrifuged at 409 g for 8 minutes and left in 2 ml
of denaturing solution (HCl 2 N) for 10 minutes. Sam-
ples were washed, resuspended in Sodium tetraborate
0.1 M, pH 8,5 for 10 minutes, washed and resuspended
for 10 minutes in 0.5% BSA and 0.1% Tween 20 in PBS.
Cells were then incubated for 45 minutes with an anti-
BrdU primary antibody (Sigma Aldrich, Milan, Italy),
washed and incubated for 30 minutes with a FITC-con-
jugated anti-mouse secondary antibody (BD Pharmin-
gen, Italy). After a wash, 200 μl of a solution with 10
mg/ml RNAase and 5 μg/ml di Propidium Iodide was
added and samples were analyzed by flow cytometry
with FACScalibur and CellQuest® analytic software (Bec-
ton Dickinson). Apoptosis was assessed by annexin V/
Propidium Iodide staining (BD Pharmingen) or, in sepa-
rate experiments, by detection of mitochondrial mem-
brane potential [37] using the 5,5’,6,6’, tetrachloro-
1,1’,3,3’-tetraethylbenzimidazolyl carbocyanin iodide dye
(JC-1) (Trevigen, Germany) according to the manufac-
turers’ instructions. In the described experiments cell
death was evaluated by the analysis of Forward/Side
scatter fluorescence changes. Fluorescence Activated
Cell Sorting (FACS) analysis was performed using a
FACS-Calibur Cell Cytometer and the CellQuest® soft-
ware (Becton-Dickinson, Italy).
Western blot (WB) and antibodies
Twenty to 40 μg of WCE or nuclear and cytoplasmic frac-
tions were subjected to SDS-PAGE and processed by
immuno-blot. Detection was performed using chemilumi-
nescence reaction (Pierce, USA). WCE and nuclear and
cytoplasmic fractions were prepared according to standard
procedures. Antibodies used: GSK-3a/b,( S a n t a - C r u z
B i o t e c h n o l o g y ,C A ,U S A ) ;G S K - 3 b, b-catenin, phospho-
Ser 21/9 GSK-3a/b, PARP, MCL-1, ERK1, 2, phospho-
Thr202/Tyr204 ERK1,2, AKT, phospho-Ser 473 AKT
(Cell Signaling Technology, MA, USA); Smac/DIABLO
(Upstate/Millipore, USA); phospho-Tyr 279/216 GSK3a/b
(Abcam, UK); Nucleophosmin (Invitrogen, CA, USA);
GAPDH (Ambion, USA); b-actin and a-tubulin (Sigma-
Aldrich, Italy);
Immunofluorescence and confocal microscopy
Preparation of cell samples was done as described [52].
For confocal imaging, a Nikon Eclipse TE300 inverted
microscope equipped with a PerkinElmer Ultraview LCI
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using the appropriate laser lines. Magnification was set at
600×, using an oil immersion objective. Antibodies used
were: GSK-3a/b, Alexa Fluor® 488 goat anti-mouse
(Molecular Probes Europe, The Netherlands). To quan-
tify cytosolic and nuclear GSK-3, 200 cells were scored
for each different condition and the mean of the percen-
tages of cells with cytosolic only and cytosolic and
nuclear GSK-3 was calculated and plotted.
Statistical analysis
Data obtained were evaluated for their statistical signifi-
cance with the two-tail paired Student’s t test or one-
way ANOVA and Bonferroni’sc o r r e c t i o na sp o s t - h o c
test for experiments with multiple observations. Values
were considered statistically significant at p values below
0.05.
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